Syndax Pharmaceuticals, Inc.
Every calculator, already run for SNDX
Open the full toolkit →You have the numbers on SNDX. Get the argument.
A written report on which of these readings actually decide the outcome for Syndax Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
12 analysts covering SNDXOwnership & short interest
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmo…
SNDX — frequently asked
Is SNDX a buy right now?
Wall Street's consensus rating on Syndax Pharmaceuticals, Inc. is Strong Buy across 12 analysts, with a mean price target of $39.45 (+97% vs. the current $19.99). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is SNDX's next earnings date?
Syndax Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 2, 2026. A full SNDX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
Compare Syndax Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Syndax Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full SNDX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Syndax Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.